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Abstract
The cellular E2 Sumo conjugase, Ubc9 interacts with HIV-1 Gag, and is important for the assembly of infectious
HIV-1 virions. In the previous study we demonstrated that in the absence of Ubc9, a defect in virion assembly was
associated with decreased levels of mature intracellular Envelope (Env) that affected Env incorporation into virions
and virion infectivity. We have further characterized the effect of Ubc9 knockdown on HIV Env processing and
assembly. We found that gp160 stability in the endoplasmic reticulum (ER) and its trafficking to the trans-Golgi
network (TGN) were unaffected, indicating that the decreased intracellular mature Env levels in Ubc9-depleted cells
were due to a selective degradation of mature Env gp120 after cleavage from gp160 and trafficked out of the TGN.
Decreased levels of Gag and mature Env were found to be associated with the plasma membrane and lipid rafts,
which suggest that these viral proteins were not trafficked correctly to the assembly site. Intracellular gp120 were
partially rescued when treated with a combination of lysosome inhibitors. Taken together our results suggest that in
the absence of Ubc9, gp120 is preferentially degraded in the lysosomes likely before trafficking to assembly sites
leading to the production of defective virions. This study provides further insight in the processing and packaging of
the HIV-1 gp120 into mature HIV-1 virions.
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Introduction
Gag (Pr55) is the predominant structural protein of HIV-1 and
drives the assembly of virus-like particle in the absence of
other viral proteins. Gag is translated on free ribosomes in the
cytoplasm where it then traffics through an ill-defined route to
the sites of assembly on the plasma membrane (PM). Gag
multimerizes and initiates the budding process as the immature
procapsid assembles. Gag is also involved in the selective
packaging of the viral genome, various cellular host factors,
and incorporation of the viral protease and replication enzymes
through co-assembly with Gag-Pol fusion proteins. The
replication enzymes are then cleaved into the mature forms
along with Pr55 during virion maturation events (Gag function
reviewed in [1–3]).
The envelope glycoprotein is an essential viral structural
protein that is incorporated into the assembling virions, and is
responsible for virion binding and entry into a target cell.
Envelope is expressed as an immature precursor protein
(gp160) within the lumen of the endoplasmic reticulum (ER).
The gp160 is highly glycosylated and forms trimers within the
ER. The sugar moieties are extensively modified as it is
trafficked to the Golgi complex where gp160 undergoes
proteolytic cleavage into gp120 and gp41. Cleavage of gp160
is believed to be mediated by furin, a host encoded protease
located in the trans-Golgi network (TGN). After cleavage, the
mature fusion competent Env is trafficked through the
unregulated secretory pathway to the PM where it is
incorporated into the assembling virions. Alternatively, the Env
in the PM can be endocytosed and recycled back to the TGN
[4–6]. Currently, the mechanism leading to Env incorporation is
still not fully understood. However, there is evidence to suggest
that under normal conditions, sequences within the cytoplasmic
tail (CT) of Env interact with the matrix (MA) domain within
Gag, resulting in the specific incorporation of the mature fusion
competent Env (reviewed in [7–10]).
HIV-1 assembly predominantly takes place at the plasma
membrane [11,12]. The assembly of a fully infectious virion
requires a coordinated effort of viral and host factors to co-
traffic the essential components to the sites of assembly, and in
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some cases excluding factors, such as tetherin and
APOBEC3G [13,14]. A large number of host factors have been
identified to interact with viral proteins to direct their correct
trafficking to the assembly sites [15]. These include KIF3A,
KIF3C, KIF4, POSH, SOCS1, Rab9 and Rab11a, AP-1, AP-2,
AP-3, Tip47, staufen, GGA and ARF, SNARE proteins, ABCE1,
CD81, phosphatidylinositol (4,5) bisphosphate, lipid rafts,
clathrin, TSG101, and AIP1 [4,6,16–37]. The exact timing and
location of where most these proteins interact during the viral
assembly pathway are still not fully understood.
One important knowledge gap is our understanding of when
and where Gag and Env first interact during the assembly
process to facilitate Env incorporation into the released virions.
Various mechanisms have been proposed for Env
incorporation. Under normal conditions, either direct or indirect
interactions between amino acids within MA and the
cytoplasmic tail of Env result in the selective incorporation of
the viral Env (reviewed in 7–10. Confocal microscopy data
examining the site of co-localization between Gag and Env
suggested that Gag and Env interact at the PM [27,38].
However various lines of evidence have suggested that the
interaction may occur before virion assembly at the PM, either
through direct or indirect interactions that result in the active
incorporation of mature Env into the assembling virions
[27,39–44]. Regardless of where Gag and Env first interact,
there is evidence to suggest that both Gag and Env influence
the stability and trafficking of each other [5,38–40,45–48],
which is important for the assembly of an infectious virion.
We have previously reported that the host factor Ubc9
interacts with Gag and plays an important role in the HIV-1
assembly pathway [49]. Ubc9 is an E2 SUMO conjugase that
post-translationally modifies target proteins and alter their
function by the addition of SUMO (reviewed in 50,51. However,
a growing list of proteins have been found to interact with Ubc9
to result in their altered function without being targets for
SUMOylation [52–59]. Ubc9 and SUMOylation have been
shown to play important roles in the replication cycles of both
DNA and RNA viruses, and some of these viruses deregulate
the host SUMOylation pathway to enhance their replication
[60–62]. We previously reported that knockdown of the
endogenous Ubc9 expression in HIV-1 producer cells results in
the production of defective virions. The defect in infectivity was
due to decreased levels of mature intracellular Env and
reduced Env incorporation into the released virions.
Interestingly, the decreased intracellular Env levels in Ubc9
knockdown cells were dependent upon Gag expression, as
intracellular Env levels were not affected in the absence of Gag
and Ubc9 expression. Experiments with the trans-dominant
negative Ubc9 (C93A), lacking the SUMO conjugase activity,
have suggested that the enzymatic activity of Ubc9 did not play
a role in Gag dependent reduction of intracellular Env levels
[49].
In order to further understand the role of Ubc9 and how its
depletion leads to the decreased levels of mature intracellular
Env to result in production of defective virions, we have
systematically examined which step(s) in the virus assembly
pathway might be affected by Ubc9 knockdown and lead to a
reduction in Env incorporation. We found that in Ubc9
knockdown cells, the decreased levels of intracellular mature
Env is not due to an increase in gp160 instability in the ER, or a
defect in subsequent trafficking to the TGN compartment. We
found that mature Env is selectively targeted for degradation,
possibly via the lysosomal pathway after it is processed from
gp160 and transported out of the TGN. We also found that
there were decreased levels of Gag and mature Env in the PM
and lipid rafts. Taken together, our findings suggest that in
Ubc9 knockdown cells, there is mistrafficking of Gag and Env
to microdomains of the PM known to be important for virion
assembly, and the degradation of mature Env likely occurred
before trafficking to the PM.
Materials and Methods
Ethics statement
Certificate of Exemption approval was obtained from the
University of Nebraska-Lincoln Institutional Review Board
under project ID 10956.
Cell culture and transfection
293T cells were obtained from the American Type Culture
Collection, they were cultured and transfected with control and
Ubc9 siRNA as previously reported [49]. TZM-bl indicator cells
were obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl from
Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.
Plasmids
The infectious HIV-1 proviral clone pNL4-3 was obtained
from the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: pNL4-3 from Dr. Malcolm Martin
[63]. The cleavage defective envelope mutant (pNL4-3 MUT
511) was a kind gift from Dr. Valerie Bosch and has been
previously described [64].
Metabolic labeling, immunoprecipitation and
Endoglycosidase treatments
Metabolic labeling experiments were carried out as
previously reported with differences in labeling times with [35S]
methionine/cysteine (>1,000 Ci/nMol; NEN) [49]. Briefly,
transfected and untransfected 293T cells were labeled for 30
minutes, 1 hour, or 4 hours with 300 µCi, 600 µCi, or 2.0 mCi
respectively. For pulse chase experiments, labeling media
were removed and chased for 2 and 4 hours in complete
culture media. The culture media was removed, clarified by
centrifugation (13,000 RPM for 2 min), and adjusted to 1X lysis
buffer [65]. Cells were lysed with 1X lysis buffer containing Halt
protease inhibitors cocktail (Pierce) and clarified by
centrifugation. Viral proteins were immunoprecipitated using
AIDS patient sera and Ultralink A/G beads (Thermo Scientific).
The beads were washed four times with lysis buffer, boiled for
5 minutes in 0.04% SDS and 200mM 2-mercapitoethanol [66].
The solublized proteins were divided into two equal aliquots
and treated with Protein N-Glycosidase F (PNGase F) or
Endoglycosidase Hf (Endo Hf) (NEB) according to
manufacturers suggestions for 3.5 hours, or left untreated. All
samples were adjusted to 1X protein sample buffer (PSB),
separated by SDS-PAGE, and visualized by phosphor imaging.
Ubc9 Involvement in Env Intracellular Trafficking
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Band intensities were quantified using Discovery Series
Quantity One software (Bio-Rad). Alternatively, viral proteins
were solublized directly from the A/G beads using 2X PSB,
boiled, gel separated and examined as above.
Inhibitor treatments
Transfected and untransfected cells were treated with
various protease inhibitors: proteasome inhibitor MG132 (10
µM) and lysosome inhibitors E63d (10 µg/ml), Pepstatin A (10
µg/ml), and Leupeptin (5 µg/ml). All inhibitors were purchased
from Sigma. Cells were pretreated with the appropriate
inhibitors prior to metabolic labeling and maintained throughout
the pulse-chase experiment. Pulse-chase samples were
processed and analyzed as above.
Unfolded protein response
Activation of the unfolded protein response was analyzed by
XBP-I splicing as previously described with slight modifications
[67]. Briefly, transfected and untransfected 293T cells were
treated with 5mM dithiothreitol (DTT) for 3 hours or left
untreated. Total RNA was extracted from 293T cells using the
RNeasy mini kit (Qiagen) and treated with DNase I
amplification grade (Invitrogen) according to manufacturer’s
protocol. Three micrograms of RNA was reverse transcribed
using oligo (dT) and SuperScript III (Invitrogen) per
manufacturer’s protocol. XBP-1 cDNA was amplified using
standard PCR techniques with primers that flank the splice site
(5’-ccttgttgagaaccagg-3’ and 5’-ctaagactaggggcttggta-3’).
Plasma membrane and Lipid raft/detergent resistant
membrane isolation
Cells were pulse labeled with [35S] methionine/cysteine for 30
minutes and chased for 1.5 and 2.5 hours. At the chase times,
cells were quickly cooled on ice. Medium was removed from
the culture dishes and cells were collected in ice-cold sucrose
buffer (16% by weight), ruptured by dounce homogenization,
and followed with Benzonase treatment (50 units) for 0.5 hours.
The plasma membrane was separated from membranous
organelles by ultracentrifugation. Samples were centrifuged at
4°C, for 20 hours at 34,500 RPMs in a ML-130 rotor.
Supernatants were carefully collected leaving behind the pellet
containing cellular organelles and adjusted to 1X lysis buffer.
Viral proteins were immunoprecipitated with HIV-1 patient
serum, separated by SDS PAGE, and visualized by
phosphorimaging using The Discovery Series Quantity One
software. Lipid raft isolations were preformed as previously
described, with slight modifications [68]. Transfected 293T cells
were radiolabeled for 4 hours with 2.0 mCi [35S] methionine/
cysteine. The labeling media was removed and the cells were
lysed on ice with 500 µl of TNE buffer (10 mM Tris [pH 7.5],
100 mM NaCl, 10 mM EGTA) containing 0.5% Triton X-100
(TX-100) for 30 min. Lysates were collected and homogenized
with 10 strokes through a 25-G needle, and then clarified by
low speed centrifugation at 10,000 RPMs at 4°C for 10
minutes. Post nuclear lysates were adjusted to 60% sucrose by
adding 1.5 ml of 80% sucrose TNE (w/v). The lysates were
layered over 500 µl of 80% sucrose TNE, followed by 2 ml of
50% sucrose TNE, 6ml of 38% sucrose TNE, and 1.5 ml of
10% sucrose TNE. The sucrose gradients were centrifuged at
100,000 X g at 4°C for at least 18 hrs in a Beckman SW41
rotor. Eleven fractions were collected using a piston gradient
fractionator (Biocomp). Densities of each fraction were
determined by the refractive index of each sample. Fractions
were adjusted to 1X lysis buffer, viral proteins were
immunoprecipitated with pooled HIV-1 patient serum,
separated by SDS-PAGE and visualized by phosphor imaging.
Cellular proteins were precipitated from each fraction by
methanol/chloroform/water precipitation [69], then analyzed by
immunoblotting to identify which sucrose fractions contained
lipid rafts (LR), detergent resistant membranes (DRM) and/or
detergent soluble membranes (DSM).
Immunoblotting
Samples were lysed in lysis buffer as previously described
[49], normalized for total protein concentration by BCA assays
(Pierce), or samples were directly solublized in 2X PSB.
Proteins were separated by SDS PAGE, transferred to
nitrocellulose membrane (GE Water & Process Technologies)
and detected by immunoblotting as previously described [49],
or with a LI-COR Odyssey infrared imaging system.
Antibodies
Anti-Ubc9 (N-15) goat polyclonal antibodies (PAb), anti-Actin
goat PAb, anti-Flotillin (K-19) goat PAb, anti-E-Cadherin
(H-108) rabbit PAb, horseradish peroxidase (HRP)-conjugated
chicken anti-goat, and HRP-conjugated donkey anti-mouse
PAb were purchased from Santa Cruz Biotechnology, Inc.
HIV-1 anti-gp120 goat PAb was purchased from Affinity
BioReagents. Anti-human transferrin receptor monoclonal
antibodies were purchased from Invitrogen. HIV-IG was
obtained from the NIH AIDS Research and Reference Reagent
Program. Alexa Fluor 488 conjugated goat anti-human PAb
were purchased from Molecular Probes (Invitrogen). IRDye
800CW conjugated donkey anti-goat and IRDye 680LT
conjugated donkey anti-rabbit PAbs were purchased from LI-
COR. Pooled HIV-1 infected patient sera were obtained from a
patient cohort.
Env cell surface expression quantification
HIV-1 envelope cell-surface expression was analyzed as
previously described [70]. Briefly, transfected 293T cells were
harvested using PBS supplemented with EDTA and EGTA and
fixed for 30 min at 4°C in 2% paraformaldehyde in PBS. To
quantify Env surface expression levels, fixed cells were
incubated with primary antibody (HIV-IG, NIH), washed
extensively and the binding of the primary antibody to the cells
was detected with Alexa Fluor-488 goat-anti-human conjugated
antibody. The mean fluorescence intensity (MFI) and percent of
fluorophore positive (Env-expressing) cells were detected with
the FACS Calibur system (BD Biosciences). For each
treatment the geometrical mean fluorescence intensity value
for the control stained population (mock-transfected cells) was
subtracted from the MFI value of the positively stained sample.
The MFI values and percentage of Env-positive cells in siRNA
transfected samples are expressed as percentages of the
values found in cells transfected with only pNL4-3.
Ubc9 Involvement in Env Intracellular Trafficking
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Results
No evidence for endoplasmic reticulum associated
degradation (ERAD), or activation of the unfolded
protein response (UPR) as a factor in gp120 stability in
Ubc9-depleted cells
To examine the possibility that in the absence of Ubc9 the
decrease in intracellular gp120 could be due to an increase in
gp160 degradation in the endoplasmic reticulum (ER), we
examined two major ER degradation pathways (ERAD and
UPR). The ERAD is an ER based pathway that degrades
misfolded proteins. Proteins targeted by ERAD are partially
deglycosylated, exported out the ER, and targeted for
degradation in a proteasome dependent manner (reviewed in
71–73. It has been previously demonstrated that treatment of
Env expressing cells with GPG-NH2 causes Env to undergo
ERAD, which results in gp160 migrating at a molecular weight
(MW) similar to wild type gp120 due to gp160 partial
deglycosylation [67,74]. If a population of gp160 was partially
deglycosylated via ERAD, it could affect the identification and
quantitation of the gp160 and gp120 levels in the Ubc9
knockdown cells. Even though our previous study analyzing
transfected cell lysates at steady state, using monoclonal
antibodies that were specific for gp120 and gp41, did not
suggest that ERAD was occurring [49], we could not rule out
the possibility that a portion of the 120 kDa proteins observed
could in fact be gp160 undergoing ERAD in our pulse chase
assays. Therefore, to examine this possibility we determined
the MW of deglycosylated viral glycoproteins after treatment
with PNGase F (Figure 1a), which hydrolizes nearly all forms of
N-linked glycans [75]. The viral glycoprotein was expressed as
gp160 during the pulse-labeling period. During the chase,
gp120 could be detected in cells transfected with pNL4-3
alone, or in combination with control siRNA. As expected, cells
transfected with Ubc9 siRNA contained less gp120. When the
lysates from the pulse period were treated with PNGase F, the
band corresponding with glycosylated gp160 disappeared and
a band with a MW of approximately 90 kDa was observed. This
90 kDa band correlates with the expected MW of
deglycosylated gp160. When the chase samples were treated
with PNGase F, the expected 90 kDa band was detected. The
band corresponding to gp120 disappeared, and a band with a
MW of approximately 60 kDa appeared, which correlates to the
expected weight of deglycosylated gp120. The 60 kDa band
was observed throughout the chase period when samples were
treated with PNGase F, and was much less evident in cells
transfected with Ubc9 siRNA. A band with a MW of
approximately 30 kDa also appeared in these samples, which
correlates with the expected size of deglycosylated gp41. The
presence of the 60 kDa band in Ubc9-depleted cell lysates
treated with PNGase F indicated that the band around 120 kDa
in the PNGase F untreated cell lysates was gp120, and not a
partially deglycosylated forms of gp160 undergoing ERAD.
More importantly, gp160 did not appear to be preferentially
degraded in Ubc9 knockdown cells as compared to control
cells. Over-exposed gels did not show any unique or additional
bands between 90 and 60 kDa, ruling out the possibility that
gp160 was undergoing degradation (data not shown).
Since ERAD is not involved, we examined if the unfolded
protein response (UPR) could be involved in the decrease of
intracellular gp120 through degradation of gp160. The UPR is
triggered when improperly folded proteins accumulate in the
ER, and is a marker for overall ER stress and cellular
dysfunction. Upon UPR activation, the X-box binding protein 1
(XBP-1) mRNA is alternatively spliced, leading to a frame-shift
that increases the transcriptional activity of XBP-1, and
upregulation of chaperones in the ER (reviewed in 76. To
examine ER stress and activation of UPR, XBP-1 splicing in
Ubc9-depleted cells was determined using total cellular RNA
extracted from transfected 293T cells, either treated or
untreated with an UPR activating agent, dithiothreitol (DTT). A
450 bp unspliced XBP-1 mRNA product was detected in
untreated cells and upon addition of DTT, a 26 bp smaller
spliced XBP-1 mRNA PCR product was detected, indicating
that the UPR was activated (Figure 1b). However, neither
HIV-1 gene expression nor knockdown of Ubc9 by siRNA
activated the UPR. Duplicate plates transfected with control
siRNA, Ubc9 siRNA, or left untransfected were lysed and
immunoblotted for Ubc9 and actin levels to confirm knockdown
of Ubc9 (Figure 1c). Taken together, the decrease in
intracellular gp120 levels did not appear to be due to enhanced
gp160 instability in the ER as an outcome of Ubc9 knockdown.
Gp160 is trafficked to the trans-Golgi network normally
in the absence of Ubc9 expression
With no evidence implicating ER dysfunction and associated
gp160 degradation in the Ubc9-depleted cells, we next
determined whether there was a defect in gp160 trafficking to
the TGN, and whether cleavage and maturation could be
involved in the decreased levels of intracellular gp120. To
determine if Ubc9 knockdown causes defects in gp160 TGN
trafficking, we tracked Env movement through the secretory
pathway of Ubc9 knockdown cells and control cells by
evaluating the glycosylation state of Env with a combination of
pulse chase analysis and Endo Hf sensitivity assay (Figure 2a).
HIV-1 gp160 is extensively modified with N and O-linked
oligosaccharides in the ER, but they can be removed by Endo
Hf, an endoglycosidase which primarily cleaves high-mannose
sugars [77]. As Env proteins trimerize in the ER and traffic
through the TGN, the polyprotein oligosaccharides are
substantially modified and the susceptibility to Endo H f
cleavage decreases. While gp160 traffics through the TGN it is
cleaved into its mature forms (gp120 and gp41) ( [78–80],
reviewed in 81. Unlike the previous and subsequent
experiments, cells were pulse labeled with [35S] methionine/
cysteine for a shorter period of time (30 minutes) in order to
monitor and quantify a more finite population of gp160 as it is
modified and trafficked through the secretory pathway. During
the pulse period (P), only gp160 could be detected in control
cells that were transfected with NL4-3 proviral DNA alone
(Figure 2a, left panel), in cells co-transfected with NL4-3 and
control siRNA (middle panel), or in cells co-transfected with
NL4-3 and Ubc9 siRNA (right panel). Treatment of the pulse
samples with Endo Hf led to the disappearance of the band of
160 kDa (gp160), and a band with an approximate MW of 90
kDa was observed. The 90 kDa band correlates with the
expected MW of gp160 with its N-linked glycans removed by
Ubc9 Involvement in Env Intracellular Trafficking
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Figure 1.  Decreased Env stability in Ubc9 knockdown cells is not due to endoplasmic reticulum stress responses.  (a)
Molecular weights of deglycosylated Env proteins in the presence or knockdown of Ubc9 expression. 293T cells were transfected
with pNL4-3 alone, or in combination with either Ctr. siRNA or Ubc9 siRNA, or left untransfected (Un). Cells were pulse (P) labeled
with [35S] methionine/cysteine for 1 hour and chased for 2 and 4 hours. Cell associated viral proteins were solublized and
immunoprecipitated with pooled AIDS patient sera, split equally, and incubated for 3.5 hours at 37°C in the presence, or absence of
N-glycosidase F (PNGase F). Samples were separated by SDS PAGE and visualized by phosphorimaging using The Discovery
Series Quantity One software. A representative over-exposed gel is shown so that partially Endo Hf resistant Env can be more
easily visualized. The identity and position of PNGase F untreated viral proteins are labeled on the left of the gel. Deglycosylated,
PNGase F sensitive, viral proteins are labeled on the right and are denoted with a (s) to identify the position of gp160s, gp120s, and
gp41s in the gel after PNGase F treatment. (b) Unfolded protein response activation state in the presence or knockdown of Ubc9
expression. Untransfected (1), NL4-3 alone (2), NL4-3 + Ctr. siRNA (3), NL4-3 + Ubc9 siRNA (4). Total RNA was extracted from
transfected 293t cells that were either treated with 5mM DTT for 3 hours to induce UPR, or left untreated. Total mRNA was reverse
transcribed with oligo (dT) followed by PCR amplification of XBP-1 cDNA using primers that flank an alternative splicing site with in
the XBP-1 mRNA. (c) Immunoblot of Ubc9 expression in whole cell lysates. Untransfected (group 1), Ctr. siRNA (group 2), and
Ubc9 siRNA (group 3).
doi: 10.1371/journal.pone.0069359.g001
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Endo Hf (gp160s). Susceptibility of gp160 to Endo Hf during the
pulse period suggests that all the gp160 was located in the ER.
As expected, during the chase period, gp160 levels decreased,
and gp120 appeared along with a very diffuse band with an
approximate MW of 170-180 kDa. This diffuse band correlates
to a population of gp160 that traffics to the Golgi and is
modified with more complex sugars [82,83]. When the chase
samples were treated with Endo Hf, gp160, gp120, and the
170-180 kDa bands disappeared, the bands with approximate
MW of 130, 90, and a smear around 80 kDa were observed.
The band at around 130 kDa is consistent with the migration
pattern of a partially Endo Hf resistant gp160 (gp160r), the
population of gp160 that would have trafficked out of the ER
with its high-mannose sugars modified to more resistant
complex sugars in the Golgi complex. The band at
approximately 90 kDa is a population of gp160 that still resides
in the ER (gp160s). The band/smear around 80 kDa is
consistent with forms of gp120 that have undergone extensive
glycosylation modifications in the Golgi and were partially
resistant to Endo Hf (gp120r) [84].
Upon transfection with Ubc9 siRNA, or with control siRNA,
levels of partially Endo Hf resistant forms of gp160 (gp160r)
were detected beginning at two hours. Detection of similar
amounts of gp160r in cells where Ubc9 expression was
knocked down indicated that gp160 was able to trimerize and
traffic out of the ER [85,86]. Mature Env gp120 and gp120r
were detected at similar levels in cells transfected with NL4-3,
or in combination with control siRNA. As expected, gp120 and
gp120r were on average reduced by 50-60% in cells
transfected with Ubc9 siRNA (Figure 2a). However, during the
chase period, similar levels of gp160 were found to traffic out of
the ER to the Golgi complex based on the amount of Endo H f
resistant gp160, and suggest that trafficking of gp160 to the
TGN in Ubc9 knockdowns was not affected (Figure 2b). The
lower intracellular gp120 in the absence of Ubc9 expression
resulted in less gp120 incorporated into the virion (Figure 2a,
lower panels).
Gp120, but not gp160 is specifically degraded in the
absence of Ubc9
Our data so far has suggested that the reduced level of
intracellular gp120 in Ubc9-depleted cells was not due to
defects associated with gp160 stability or trafficking. To
examine whether gp120 was specifically degraded after gp160
cleavage in Ubc9 knockdown cells, we examined the stability of
an Env cleavage provirus mutant (MUT 511). MUT 511 has a
point mutation at position 511 (Arg to Ser) in gp160, which
blocks its cleavage into gp120 and gp41. MUT 511 Env is not
efficiently incorporated into virions, but still traffics to the
plasma membrane [64,87]. If gp120 is specifically targeted for
degradation, MUT 511 Env stability should be unchanged as it
trafficks through the secretory pathway to the plasma
membrane. Cells were pulse chased and treated with Endo Hf
as in previous experiments to track MUT 511 Env stability and
trafficking through the TGN (Figure 3a). As expected, only
gp160 was observed, and it was not processed into gp120 and
gp41 because of the mutation. During the pulse period, gp160
resided in the ER and was fully Endo Hf sensitive as observed
earlier (Figure 3a). At the two-hour chase time a band with an
approximate MW of 180 kDa appeared and persisted through
the 4-hour chase period. Endo Hf treatment resulted in the
appearance of band of 90 kDa (gp160s), a partially resistant
Endo Hf gp160 (gp160r) as observed earlier (Figure 3a),
confirming that MUT 511 gp160 was trafficking through the
secretory pathway even in Ubc9 knockdown cells. Intracellular
Env levels remained stable during the chase in cells that were
transfected with either Ubc9 siRNA or control siRNA, indicating
that the decrease in gp160 observed over time in previous
experiments was due to gp160 maturation into gp120/gp41 and
not due to degradation.
Ubc9 knockdown does not affect Furin activity or
endogenous E-cadherin stability
To further confirm that the increase in gp120 degradation in
Ubc9 knockdown cells is specific to mature Env, and not due to
a more generalized decrease in overall stability of proteins
trafficking through the secretory pathway, we assayed the
maturation and stability of endogenous, cellular E-cadherin. E-
cadherin is a cellular, type-1 transmembrane adhesion factor
and its biosynthetic pathway is very similar to that of HIV-1
Env. E-cadherin is cleaved into its functional subunits as it
moves through the secretory pathway, presumably by Furin in
the TNG, as it traffics to the plasma membrane (reviewed in
88,89. Equal amounts of whole cell lysates from control or
Ubc9 siRNA transfected, and untransfected 293T cells were
analyzed for E-cadherin expression. Pro-E-cadherin (135 kDa)
and mature E-cadherin (120 kDa) can be detected in whole cell
lysates transfected with Ubc9 siRNA, albeit at a slightly lower
amount of total E-cadherin (immature and mature forms) as
compared to control cells (on average 19-23% less). The lower
E-cadherin expression was not unexpected as previous studies
have shown that intracellular levels of Ubc9 regulate E-
cadherin expression through miR-200b [90–93]. Even though
less total E-cadherin was expressed in the Ubc9 knocked down
cells, the mature E-cadherin represented 43% of total cellular
E-cadherin when normalized to the levels of actin regardless of
Ubc9 expression (Figure 3b). Our results indicate that in Ubc9-
depleted cells, there was no evidence of a general decrease in
stability of proteins such as E-cadherin while trafficking through
the secretory pathway. In addition, Furin activity was not
affected, as judged by pro-E-cadherin cleavage and suggest
that the lower levels of gp120 in Ubc9 knockdown cells is not
due to deficient Furin-mediated gp160 cleavage.
Degradation of gp120 occurs before transport to the
plasma membrane and the lipid rafts
Our results have indicated that gp160 stability, trafficking
from the ER to the TGN, and cleavage was normal. In a normal
cell, after Env cleavage maturation occurs, the trimer consisting
of gp120 and gp41 is trafficked to the PM. The mature Env is
then either incorporated into assembling virions, or it is quickly
endocytosed by the cellular endocytic machinery through
interactions with adaptor protein complexes primarily through
AP-2 binding [6,24,94]. It is possible that in the absence of
Ubc9, gp120 stability is affected prior to reaching the PM or
may be affected only after endocytosis. To further delineate
when the degradation of gp120 occurred in the Ubc9
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Figure 2.  HIV-1 gp160 traffics to the Golgi network in Ubc9 knockdown cells.  (a) Env trafficking through the secretory
pathway. 293T cells were transfected with pNL4-3 alone, or in combination with either Ctr. siRNA or Ubc9 siRNA, or left
untransfected (Un). Unlike the previous and subsequent experiments, cells were pulse (P) labeled with [35S] methionine/cysteine for
a shorter period of time (30 minutes) and chased for 2 and 4 hours. Cell and media associated viral proteins were solublized and
immunoprecipitated with pooled AIDS patient sera, split equally, and incubated for 3.5 hours at 37°C in the presence, or absence of
Endo H f. Samples were separated by SDS PAGE and visualized by phosphorimaging using The Discovery Series Quantity One
software. A representative, over-exposed gel is shown so that partially Endo Hf resistant Env can be more easily visualized. Viral
proteins and their positions in the gel are labeled on the left. The identity of Endo Hf, untreated viral proteins and their positions in
the gel are labeled on the right. Deglycosylated Endo Hf sensitive forms of gp160 residing in the ER are labeled as gp160s. Partially
deglycosylated, Endo Hf resistant forms of gp160 and gp120 that have undergone glycan modification in the TGN are labeled as
gp160r and gp120r. gp160r in Endo Hf untreated samples is labeled as gp160*. (b) The gp160 trafficking to TGN. The ratio of
gp160r/total gp160 during the 2-hour chase period, normalized to NL4-3.
doi: 10.1371/journal.pone.0069359.g002
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knockdown cells, we conducted experiments to examine the
amount of gp120 associated with the PM and lipid rafts. To
examine the levels of mature Env (gp120) associated with the
PM, Ubc9-specific or control siRNA transfected 293T cells
were metabolically labeled and chased for 1.5 and 2.5 hours
(Figure 4a), lysed and fractionated by ultracentrifugation to
Figure 3.  Stability of gp160 is unchanged in Ubc9 knockdown cells.  (a) 293T cells were transfected with pNL4-3 MUT 511
alone, or in combination with Ctr. siRNA or Ubc9 siRNA, or left untransfected. Cells were pulse (P) labeled with [35S] methionine/
cysteine for 1 hour, then chased for 2 and 4 hours. Samples were processed as described in previous Endo H f experiment. A
representative over-exposed gel is shown so that partially Endo Hf resistant Env can be more easily visualized. The identity of Endo
Hf, untreated viral proteins and their positions in the gel are labeled on the right. Deglycosylated Endo Hf sensitive forms of gp160
residing in the ER are labeled as gp160s. Partially deglycosylated, Endo Hf resistant forms of gp160 that have undergone glycan
modification in the TGN are labeled as gp160r. These forms of gp160 denoted as gp160* in Endo Hf untreated samples. Lower
panel: Immunoblot of Ubc9 expression in whole cell lysates; untransfected (group 1), pNL4-3 (group 2), Ctr. siRNA (group 3), and
Ubc9 siRNA (group 4). (b) Furin activity is not dependent upon Ubc9 expression. 293T cells were lysed 24 hrs post transfection and
cell lysates were immunoblotted with antibodies against Ubc9, Actin, and E-Cadherin. Immature, uncleaved E-Cadherin is
designated as pro E-Cadherin.
doi: 10.1371/journal.pone.0069359.g003
Ubc9 Involvement in Env Intracellular Trafficking
PLOS ONE | www.plosone.org 8 July 2013 | Volume 8 | Issue 7 | e69359
separate the PM from other cellular organelles. During the
pulse, very little Env proteins appeared to be associated with
the PM fraction in any samples. At 1.5 and 2.5 hours, gp160
and gp120 can be readily detected in the PM fraction of cells
transfected with NL4-3 alone, or with NL4-3 and control siRNA.
Cells transfected with NL4-3 and Ubc9 siRNA showed an 83%
decrease in the levels of gp120 associated with the PM fraction
as compared to the control cells (Figure 4b). Surface
expression of Env examined by confocal microscopy (data not
shown) and flow cytometry at steady state levels confirmed that
less Env was expressed on the cell surface in Ubc9 knockdown
cells (Figure 4c). Together, these results suggested that in
Ubc9 knockdown cells, less Env is present at the plasma
membrane, and gp120 stability was affected prior to its
insertion into the PM.
To more extensively examine the amount of Gag and Env
associated with the PM during the assembly process we
analyzed their association with lipid rafts (LR). Multiple lines of
evidence have implicated that lipid rafts are important
microdomains of the PM that facilitate virion assembly
(reviewed in 95,96. To examine viral protein association to lipid
rafts in Ubc9 knockdown cells, metabolic labeling combined
with lipid raft floatation experiments were utilized. Transfected
293T cells were metabolically labeled, the cell lysates were
fractioned, and analyzed for the presence or absence of viral
and cellular proteins. Flotillin-1 is a protein marker of cellular
LR and was only detected at the top of the gradient in fractions
1 and 2. Transferrin receptor (TfR), a protein excluded from
detergent resistant membranes (DRM) and lipid rafts, was only
detected in the bottom of the gradient in fractions 9, 10, and 11,
indicating that there was a good separation between LR, DRM,
and detergent soluble membranes (DSM) (Figure 5a). The
densities of each of the fractions across all samples were
assayed and showed that the gradients were consistent and
reliably reproduced among samples (Figure 5b). DSM fractions
from transfected cells were combined and immunoblotted for
Ubc9 expression (Figure 5c). The majority of Gag and Env
were detected in the DSM fractions, with very small amount
found in the DRM and LR fractions regardless whether the cells
were co-transfected with control siRNA, Ubc9 siRNA, or with
NL4-3 alone (Figure 5d–f). In cells transfected with NL4-3, or in
combination with control siRNA, gp160, gp120 and Gag were
detected in the DSM and LR fractions. Viral proteins associated
with DRM decreased as the sucrose density decreased
towards the top of the gradient, then increased again when the
fractions were enriched with LR. The ratios of Pr55 with gp160
and/or gp120 in LR fractions were similar between control cells.
Interestingly, cells co-transfected with NL4-3 and Ubc9 siRNA
showed altered levels of viral proteins associated with the DSM
and LR factions. Ubc9 siRNA transfected cells showed about a
5-fold reduction in the amount of gp120 associated with LR
fractions. However, similar LR Pr55/gp160 ratio was found
when compared to control cells, suggesting that the amount of
gp160 associated with the LR was not affected by Ubc9
expression levels even though there was a reduction in gp120
level (Figure 5g). The percentage of Gag associated with LR
was also examined, as previous reports have suggested that
Env trafficking to LR is dependent upon Gag co-trafficking to
LR [97,98]. We found that in the absence of Ubc9 expression,
Pr55 association with LR was decreased by almost 50%
compared to the control cells (Figure 5h). We observed a good
correlation between results obtained by three different technical
approaches (i.e. membrane fractionation, floatation assay, and
cell-surface envelope expression measurement by flow
cytometry). In summary, our data suggests that Gag and Env
trafficking and association with the plasma membrane is
altered in the absence of Ubc9, and that gp120 stability is
affected prior to the trafficking of gp120 to the PM and to the
lipid raft microdomain in Ubc9 knockdown cells.
Intracellular gp120 is degraded through the lysosomal
pathway in the absence of Ubc9
To further understand how Env stability is affected in Ubc9
knockdown cells, we examined whether any of the predominant
degradation pathways are involved. For these experiments we
examined if proteasomal or lysosomal inhibitors will impede the
degradation of mature Env in an effort to determine which
degradative pathway was involved with Env degradation in
Ubc9 knockdown cells.
To examine the potential participation of the proteasomal
degradation pathway MG132 (10µM) was used to inhibit the
ubiquitin dependent 26S proteasome, and Env stability was
assayed by pulse-chase experiments. We began by examining
the proteasome as it has been previously demonstrated that
the proteasomal pathway plays a crucial role during virion
assembly and release [99]. Interestingly, no significant changes
in Env maturation or stability was observed in the presence of
the inhibitors, even though it has been reported by Bultmann et
al. that a small fraction of Env is ubiquitinated and is degraded
through the proteasome pathway [100]. In cells transfected with
Ubc9 siRNA and NL4-3 in the presence of MG132, Gag
displayed an assembly phenotype similar to what was
described by Schubert et al. when cells were treated with
proteasome inhibitors (Figure 6). Less Env and Gag proteins
were expressed, Gag processing was slightly slower than in
the untreated cells with less cell associated p24/25, and virion
release was decreased by approximately 3.5-fold in the
presence of MG132 (data not shown). Intracellular gp120
levels in Ubc9 siRNA cells did not appear to increase in the
presence of MG132, suggesting that the proteasome is not the
major degradation pathway involved in affecting the stability of
intracellular gp120 in cells depleted of Ubc9.
The demonstration that the proteasome inhibitor MG132 was
unable to restore intracellular Env levels, led us to further
examine the potential role of the lysosomal degradation
pathway. The lysosome pathway has been previously
implicated as having a role in HIV-1 Env degradation and virion
assembly. A combination of specific lysosomal protease
inhibitors, E64d, Pepstatin A, and Leupeptin [101–103] were
used to determine if lysosomal degradation was involved in
Env degradation in Ubc9-depleted cells (Figure 7). In the
presence of these lysosome inhibitors, there were 40% more
intracellular gp120 at the 4-hour chase time as compared to
untreated Ubc9 knocked down cells (Figure 7). Immunoblots of
intracellular Env following longer inhibitor treatments were also
in agreement with pulse chase data using lysosomal inhibitors
(data not shown), suggesting that the lysosome degradation is
Ubc9 Involvement in Env Intracellular Trafficking
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e69359
Figure 4.  HIV-1 proteins exhibit altered trafficking to the plasma membrane in Ubc9 knockdown cells.  (a) 293T cells were
transfected with pNL4-in combination with either Ctr. siRNA or Ubc9 siRNA. Cells were pulse labeled with [35S] methionine/cysteine
for 30 minutes and chased for 1.5 and 2.5 hours. At indicated times, cells were ruptured and treated with Benzonase (50 units) for
0.5 hours. Lysates were centrifuged at 4°C, for 20 hours at 34,500 RPMs in a ML-130 rotor. Supernatants were carefully collected
leaving behind the pellet containing cellular organelles and adjusted to 1X lysis buffer. Viral proteins were immunoprecipitated with
patient serum, separated by SDS PAGE, and visualized by phosphorimaging using The Discovery Series Quantity One software. (b)
Quantitation of viral proteins associated with the plasma membrane. gp120/Pr55 ratios of the PM fraction during the 1.5 hour and
2.5 hour chase times. (c) Steady state Env surface expression. Transfected cells were resuspended in PBS, fixed, and surface Env
was assayed by flow cytometry using HIV-IG and Alexa Fluor-488 goat-anti-Human conjugated Antibodies.
doi: 10.1371/journal.pone.0069359.g004
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Figure 5.  HIV-1 Gag and Env exhibit altered association with lipid rafts in Ubc9 knockdown cells.  (a) Lipid raft isolation.
Representative immunoblot of sucrose fractions for lipid raft markers Flotillin-1 and non-raft marker transferrin receptor 1 (TfR).
Fractions containing lipid raft markers (LR), detergent soluble membranes (DSM; raft excluded), and detergent resistant membranes
(DRM; non DSM). (b) Average density of all sucrose fractions prior to being adjusted to 1X lysis buffer. 293T cells were transfected
with pNL4-3 alone (c), or in combination with either Ctr. siRNA (d) or Ubc9 siRNA (e). Cells were labeled with [35S] methionine/
cysteine for 4 hours. Cells were placed on ice and transferred to a 4°C cold room where they were lysed with ice cold TNE buffer for
30 minutes on ice followed by homogenization with a 25G needle. Lysates were clarified in a cooled micro centrifuge and then
adjusted to 60% sucrose and overlaid with a discontinuous sucrose gradient and centrifuged at 100,000 X g at 4C for at least 18
hrs. Gradients were fractioned into 11 equal samples using a Biocomp piston fractionator and adjusted to 1x lysis buffer. Viral
proteins were immunoprecipitated with patient serum, separated by SDS PAGE, and visualized by phosphorimaging using The
Discovery Series Quantity One software. Lipid raft floatation experiments were carried out in triplicate. Representative over-exposed
gels are shown so that viral proteins associated with lipids rafts can be more easily visualized. (f) Immunoblot of transfected cell
lysates; untransfected (lane 1), NL4-3 + Ctr. siRNA (lane 2), NL4-3 + Ubc9 siRNA (lane 3). (g) Ratio of gp120/Pr55 proteins
associated with lipid rafts. (h) Percent of total cellular Gag associated with lipid rafts.
doi: 10.1371/journal.pone.0069359.g005
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likely to be involved in the depletion of intracellular gp120 in
Ubc9 knockdown cells.
Discussion
In this study we have continued to decipher the role of Ubc9
on HIV-1 assembly, and to further understand how Ubc9 and
Gag contribute to intracellular Env stability and incorporation
into assembling virions. We found that in Ubc9 knockdown
cells the decrease in intracellular gp120 levels is due to
increased degradation of mature Env in the lysosome at a post-
TGN trafficking step. Analysis of Env trafficking to the PM by
various assays suggests that degradation of mature Env likely
occurs before insertion into the PM. Lysosome inhibitors
partially restored mature intracellular Env levels.
Based on our results, we hypothesize two potential
mechanisms that may explain how interrupting the interaction
between Gag and the cellular host factor Ubc9 may lead to
gp120/gp41 degradation and decreased incorporation into the
assembling virions (Figure 8). In the first model, Gag
intracellular trafficking is affected due to the Ubc9-depletion.
The change in Gag trafficking alters the Env-Gag interaction to
cause mature Env to be mistargeted for degradation before its
transport to the PM. The second model proposes that depletion
of Ubc9 diminishes the ability of Gag to stabilize Env on the
PM, leading Env to be quickly endocytosed and targeted for
degradation in the lysosome instead of recycling in the TGN
[4].
Our results favor the first model. The altered Gag-Env
interaction in Ubc9 knockdown cells may directly or indirectly
led to the mistargeting of the Env containing secretory vesicles
for degradation before trafficking to the PM. In Ubc9-depleted
cells, Gag displayed altered trafficking and association with
lipid rafts, a microdomain important during the very late stages
of virion assembly (reviewed in 95,96. We have previously
observed that Gag co-localized with Ubc9 in close proximity to
the PM, and suggests that this interaction may be important
during the later stages of virion assembly [49]. However, the
earlier stages of Gag trafficking may have also been disrupted
since Ubc9 was identified as a host factor localized to the Gag
perinuclear clusters (GPC), which were hypothesized to be the
early intermediate Gag trafficking sites [18]. When Ubc9 is not
present at the GPC, Gag may not be targeted correctly through
the cytoplasm, and affects its interaction with other viral and
cellular factors during virion assembly.
Env and Gag have been hypothesized to first interact and
influence each other at an intracellular site, at or near the TGN
Figure 6.  Env and Gag stability in Ubc9 knockdown cells in the presence of proteasome inhibitor MG132.  293T cells were
transfected with Ubc9 siRNA and pNL4-3 as in previous experiments. MG132 (10µM) was added to the culture media for 1 hour
prior to pulse chase experiments and was maintained throughout the experiment. Cells were pulse (P) labeled with [35S] methionine/
cysteine for 1 hour and then chased for 2 and 4 hours. Cell and media associated viral proteins were solublized and
immunoprecipitated with pooled AIDS patient sera, split equally, and incubated for 3.5 hours at 37°C in the presence, or absence of
Endoglycosidase H f (Endo H f). Samples were separated by SDS PAGE and visualized by phosphorimaging using The Discovery
Series Quantity One software. A representative, over-exposed gel is shown so that partially Endo Hf resistant Env can be more
easily visualized. Viral proteins and their positions in the gel are labeled on the left. The identity of Endo Hf, untreated viral proteins
and their positions in the gel are labeled on the right. Deglycosylated Endo Hf sensitive forms gp160 residing in the ER are labeled
as gp160s. Partially deglycosylated, Endo Hf resistant forms of gp160 that have had their glycans modified in the TGN are labeled
as gp160r. Forms of gp160 that have undergone glycan modification in the TGN but have not been cleaved are denoted as gp160*
in Endo Hf untreated samples.
doi: 10.1371/journal.pone.0069359.g006
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Figure 7.  HIV-1 gp120 is degraded through the lysosomal pathway in Ubc9 knockdown cells.  293T cells were transfected
with Ubc9 siRNA and NL4-3 as in previous experiments. (a) A combination of E64d (10µM), Pepstatin A (10µM), and Leupeptin
(5µM), was added to the culture media 2 hours, or 45 minutes prior to pulse chase experiments. The amount of Pepstatin A was
increased to 50 µM during the pulse chase experiment, while the amounts of E64d and Leupeptin were maintained at 10 µM and 5
µM respectively. Cells were pulse labeled with [35S] methionine/cysteine for 1 hour and then chased for 2 and 4 hours. Cell and
media associated viral proteins were solublized and immunoprecipitated with pooled AIDS patient sera. Samples were separated by
SDS PAGE and visualized by phosphorimaging using The Discovery Series Quantity One software. (b) Quantitation of increase in
intracellular gp120 in Ubc9 siRNA knockdown cells compared to control cells.
doi: 10.1371/journal.pone.0069359.g007
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or recycling endosomes [19,26,27,43]. It is possible that the
interruption of normal Gag-Ubc9 interactions in the Ubc9–
depleted cells may also affect Gag-Env interactions to lead to a
disruption of their co-trafficking to the site of assembly. This
disruption could lead to Env being mistrafficked/sorted and
targeted for degradation instead of trafficking to the normal
virion assembly site. This is supported by reports implicating
Ubc9 involvement in TGN protein sorting, leading to aberrant
trafficking within the cell. Studies with GLUT4, an insulin-
regulated glucose transporter have shown that Ubc9 plays a
role in regulating GLUT4 stability and trafficking [57]. GLUT4
expression was decreased by approximately 50% in Ubc9-
depleted cells due to an increase in its degradation. It was
hypothesized by Liu et al. that Ubc9 may interact with the Arf-
Figure 8.  Working model of Env trafficking through the cell in Ubc9 knockdown cells.  HIV-1 Env trafficking from the ER to
the TGN occurs normally. After cleavage into gp120/gp41 and transport out of the TGN, Env is targeted for degradation in the
lysosome instead of the assembly site of the plasma membrane. This mistrafficking of Env for degradation could be due to altered
interactions with Gag, as Gag itself is mistrafficked to the assembly site in Ubc9 knockdown cells. Another potential mechanism is
that as Gag is mistrafficked to the assembly site in Ubc9 knockdown cells, it may not stabilize Env at the plasma membrane causing
Env to be quickly endocytosed and degraded. In Ubc9 knockdown cells, a portion of endocytosed Env may then be targeted for
degradation in the lysosome instead of recycling back to the TGN. Alternatively, the trafficking or function of yet unknown cellular
factor(s) that are involved in Env stability and packaging into assembling virions may have been disrupted possibly altering Gag/
Ubc9 interactions (question mark).
doi: 10.1371/journal.pone.0069359.g008
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binding proteins (GGA), whose function is to sort proteins
moving through the secretory pathway and are involved with
the formation of GLUT4 storage vesicles. Their results suggest
that Ubc9 may function to negatively regulate the trafficking of
secretory vesicles from the TGN to sites of degradation [57].
Interestingly, GGA and Arf proteins were shown by Joshi et al.
to be important host factors that regulate HIV-1 assembly and
release, and GGA2 appeared to play a role in Env maturation
[29]. However, our data indicate that the Ubc9 knockdown
mediated decrease of intracellular levels of gp120 does not
appear to be via the same mechanism, as we have not
observed changes in gp160 processing as was reported with
GGA2 over-expression.
It is also possible that Gag and Ubc9 are part of a larger
complex that is not yet characterized, and disruption of the
normal Ubc9-Gag interaction interferes with the normal function
or composition of this complex. Disruption of this complex may
result in the mistrafficking/sorting of Env to increase the
degradation of Env in the lysosome. In this complex, Gag may
be “tethering” and retaining Ubc9 in close proximity to other
proteins within the complex to increase their interaction with
Ubc9. For example, it has been previously reported that
interactions between cellular factor p14ARF and Ubc9 enhanced
the SUMOylation of p14ARF binding partners. This demonstrated
that Ubc9 binding to cellular factors may act as a “tether” to
retain the SUMO-Ubc9 complex in close proximity to
unmodified target proteins in order to increase the efficiency by
which they are SUMOylated [104]. A similar model has been
proposed for dynamin and SUMOylation mediated endocytosis
[105].
Although we had previously reported that over-expression of
the catalytically inactive trans-dominant negative Ubc9 mutant
(C93A) did not lead to a decrease in infectivity of the HIV-1
virion produced, a total block in SUMOylation was unlikely [49],
and it is possible that only a very low level of SUMOylation is
needed during the assembly process. Interestingly, Zamborlini
et al. demonstrated that HIV-1 Gag-Pol cleavage intermediates
are SUMOylated with SUMO-2 in a cell line that over-
expressed SUMO-2. However, mutations of the SUMO
acceptor sites within integrase did not affect the enzymatic
activity of integrase or virion assembly. This suggests that if
SUMOylation of Gag-Pol plays a role during assembly it may
be at an early assembly event and must be transient since
SUMO or SUMOylated forms of Gag, or integrase have not
been detected under normal conditions [106–108].
Our data cannot completely rule out the alternative model
involving endocytosis since the SUMOylation pathway has
been previously reported to be involved in the endocytosis of
cellular proteins [105,109]. We observed changes in Gag
trafficking to lipid rafts in Ubc9 knockdown cells, which may
affect Env stability on the PM due to changes in Gag/Env
interactions and Env recruitment to lipid rafts. Our attempts to
block endocytosis using the commonly used endocytosis
inhibitor Chlorpromazine was unsuccessful because we found
that the treatment also blocked Env transport to the TGN from
the ER (data not shown). However, we do not believe that
altered endocytosis of Env, directly or indirectly, is the primary
mechanism leading to increased intracellular Env degradation
in the lysosome. It has been shown that point mutations in
either MA or the CT of Env, that disrupt Env incorporation by
altering their direct or indirect interactions at the site of
assembly, did not decrease the intracellular levels of Env as
was observed in our Ubc9 knockdown cells [97,110–113].
Furthermore, knockdown of Tip47, a host protein reported to be
involved in Env incorporation and retrograde transport to the
TGN from the PM, did not result in decreased intracellular Env
levels [4,26,27]. In addition we did not observe changes in
intracellular levels of host cell surface proteins E-cadherin
(Figure 3) and TfR (data not shown), both of which also
undergo AP-2/clathrin dependent endocytosis [114–116]. Our
data thus suggests that endocytosis dependent degradation in
Ubc9 knockdown cells is not upregulated, and is in agreement
with what others have reported with Ubc9 knockdown [109].
Interestingly, the matrix mutant (HXB2WANEO) has been
described to affect mature intracellular levels of Env in a very
similar manner to what we have described here [48]. This
similarity suggests that a disruption in MA and Env CT
interactions in Ubc9-depleted cells could lead to enhanced Env
degradation. However, other mutations within MA or Env CT
that have also been described to block Env incorporation did
not seem to affect the intracellular Env levels, or Env trafficking
to the PM [110–113]. Since the Env of these mutants
presumably undergo increased endocytosis from the PM due to
the interruption of MA/CT. These studies suggest that the
decreased levels of intracellular gp120 levels in Ubc9-depleted
cells we observed is not due to endocytosis, and is likely due to
a mechanism that is distinct from the other MA/CT mutants that
disrupt Gag/Env interactions. Furthermore, in the absence of
Gag expression, Env does not exhibit decreased intracellular
levels. This would be observed in Ubc9-depleted cells if
degradation following endocytosis was responsible for reduced
levels of intracellular mature Env, or if Ubc9 acts directly with
Env to regulate its trafficking and stability. Taken together,
increased endocytosis due to the inability of Gag to stabilize
Env at the PM, or non-specific endocytosis is not likely to be
the primary mechanism for decreased Env stability in Ubc9
depleted cells.
Extensive studies have been carried out to characterize the
functions of Env CT using point mutations and deletions,
however the precise molecular mechanisms of how Gag and
Env coordinate the assembly of infectious virions on the
plasma membrane remains elusive (Reviewed in 7–10.
Interestingly, careful characterization of a panel of CT deleted
HIV-1 Env mutants displayed defects in almost every functional
assay with the exception that mutant gp41 was found to be
incorporated at a higher level with extracellular virions than with
WT. However, less gp120 was co-incorporated with the mutant
gp41 [117]. Based on our data, one might hypothesize that this
mutant my be resistant to Ubc9 knockdown based on our data
and hypothesis, however this mutant displays multiple defects
in processing, stability, and trafficking making it difficult to
analyze the domains involved upon depletion of Ubc9 in HIV-1
producer cells. Future studies will be needed to more closely
examine and identify which regions and amino acids that are
required for the Env degradation phenotype in Ubc9 depleted
cells.
In conclusion, our study further support that Ubc9, through
interactions with Gag, influence the stability and trafficking of
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mature HIV-1 Env to the site of assembly and ultimately affects
the amount of mature Env incorporated into released virions.
This data provides further insight as to how Ubc9 is involved in
HIV-1 assembly and could provide new strategies for antiviral
drug development.
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